A 42-year-old woman with poorly controlled type 2 diabetes mellitus presents with a 3-week history of vulvovaginal itching, burning, and thick white vaginal discharge. Pelvic examination reveals erythema and white plaques on the vaginal mucosa. KOH mount of vaginal discharge shows pseudohyphae and budding yeast. She has no prior antifungal exposure. Which antifungal agent is the most appropriate first-line treatment for this patient?

Explanation

## Diagnosis & Management of Vulvovaginal Candidiasis ### Clinical Recognition The patient presents with classic features of vulvovaginal candidiasis (VVC): - Vulvovaginal itching and burning - Thick white vaginal discharge - Erythema and white plaques on examination - KOH mount confirmation of *Candida* (pseudohyphae and budding yeast) - Risk factor: poorly controlled diabetes (hyperglycemia promotes fungal growth) ### First-Line Antifungal Choice **Key Point:** Fluconazole 150 mg oral single dose is the gold standard first-line treatment for uncomplicated vulvovaginal candidiasis in non-pregnant, immunocompetent women. **High-Yield:** Oral azoles (fluconazole, itraconazole) are preferred over topical agents for systemic efficacy and patient convenience in acute VVC. ### Mechanism of Fluconazole - Selective inhibitor of fungal lanosterol 14α-demethylase (cytochrome P450 14DM) - Disrupts ergosterol synthesis in fungal cell membrane - Fungistatic action against *Candida* species - Excellent vaginal tissue penetration ### Dosing Rationale for VVC | Indication | Dose | Duration | | --- | --- | --- | | Uncomplicated VVC | 150 mg PO single dose | Single dose | | Complicated VVC | 150 mg PO | Repeat dose at 72 hours | | Recurrent VVC | 150 mg PO | Weekly × 6 months (maintenance) | **Clinical Pearl:** A single 150 mg dose achieves >90% cure rate in uncomplicated VVC. Repeat dosing is reserved for complicated cases (pregnancy, immunosuppression, severe symptoms, non-albicans species). ### Why Fluconazole Over Topical Agents? - Oral route improves compliance - Systemic distribution ensures adequate vaginal levels - Faster symptom resolution - Topical agents (clotrimazole, miconazole) are acceptable alternatives but require 3–7 day courses ### Special Considerations in This Patient - Diabetes: hyperglycemia increases VVC risk; glycemic control is essential for prevention - No immunosuppression documented: oral azole is safe and effective - No pregnancy: fluconazole is contraindicated in first trimester (teratogenic); safe in non-pregnant women [cite:KD Tripathi 8e Ch 49]